FDA approves Farxiga

The FDA approves AstraZeneca (AZN +0.3%) and Bristol-Myers Squibb's (BMY +1.2%) Farxiga (dapaglifozin).

The drug is intended to improve glycemic control in adults with Type 2 diabetes.

Farxiga isn't recommended for patients with active bladder cancer and the regulator is "requiring six post-marketing studies," including a CVOT.


From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs